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Abstract
Background: One primary goal of transcriptomic studies is identifying gene expression patterns correlating with disease
progression. This is usually achieved by considering transcripts that independently pass an arbitrary threshold (e.g. p,0.05).
In diseases involving severe perturbations of multiple molecular systems, such as Alzheimer’s disease (AD), this univariate
approach often results in a large list of seemingly unrelated transcripts. We utilised a powerful multivariate clustering
approach to identify clusters of RNA biomarkers strongly associated with markers of AD progression. We discuss the value of
considering pairs of transcripts which, in contrast to individual transcripts, helps avoid natural human transcriptome
variation that can overshadow disease-related changes.
Methodology/Principal Findings: We re-analysed a dataset of hippocampal transcript levels in nine controls and 22
patients with varying degrees of AD. A large-scale clustering approach determined groups of transcript probe sets that
correlate strongly with measures of AD progression, including both clinical and neuropathological measures and quantifiers
of the characteristic transcriptome shift from control to severe AD. This enabled identification of restricted groups of highly
correlated probe sets from an initial list of 1,372 previously published by our group. We repeated this analysis on an
expanded dataset that included all pair-wise combinations of the 1,372 probe sets. As clustering of this massive dataset is
unfeasible using standard computational tools, we adapted and re-implemented a clustering algorithm that uses external
memory algorithmic approach. This identified various pairs that strongly correlated with markers of AD progression and
highlighted important biological pathways potentially involved in AD pathogenesis.
Conclusions/Significance: Our analyses demonstrate that, although there exists a relatively large molecular signature of AD
progression, only a small number of transcripts recurrently cluster with different markers of AD progression. Furthermore,
considering the relationship between two transcripts can highlight important biological relationships that are missed when
considering either transcript in isolation.
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Introduction
Alzheimer’s disease (AD) is an irreversible brain disease that
begins with mild memory impairment but eventually progresses to
severe brain dysfunction and dementia. The prevalence of AD is
rising dramatically due to an increasingly ageing population [1].
Early diagnosis is challenging as it can be difficult to discriminate
the initial manifestations of the disease from cognitive decline that
occurs as a function of normal aging [2]. Intensive efforts are being
made to better understand AD and identify appropriate
treatments, however the molecular mechanisms underlying the
disease are still far from being understood.
In 2004, Blalock and colleagues [3] made an important
contribution towards finding a set of molecular biomarkers that
correlate with the progression of AD in one region of the brain.
Using microarray technology, they assessed RNA transcript levels
in post-mortem hippocampal tissue from 9 controls and 22
patients with varying degrees of AD severity. Participants were
categorized, based primarily on Mini-Mental State Examination
(MMSE) score [4], into one of four clinical groups: Control,
Incipient AD, Moderate AD or Severe AD (see Materials and
Methods for details of classification).
A total of 22,286 probe sets for protein coding RNA (i.e.
mRNA) and non-coding RNA (ncRNA) were used to interrogate
the transcriptome. After excluding probe sets with signals below
detection thresholds and probe sets targeting unidentified
transcripts (e.g. expressed sequence tags), Blalock and colleagues
assessed the Pearson’s correlation of each of the remaining 9,921
probe set values with MMSE score and neurofibrillary tangle
(NFT) count. This analysis revealed 3,413 genes that are
significantly correlated (at p,0.05) with MMSE score, NFT count
or both [3].
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In 2010, Gomez Ravetti and colleagues (including two authors
of this contribution) re-analyzed the publicly available dataset of
Blalock using a different method, uncovering a 1,372-probe set
signature that presents a remarkably high consensus with
established phenotypic markers of AD progression [5]. Instead
of just assessing correlations between gene expression and clinical
measures of AD (such as MMSE score or NFT count), they
employed an integrated approach based on combinatorial
optimization techniques [6,7] and Information Theory. Briefly,
divergence of the gene expression profile of each individual sample
from the average characteristic profile of the ‘‘Control’’ group was
computed using the Jensen-Shannon divergence [8]. Similarly, this
approach was used to compute the convergence of the gene
expression profile of each individual sample to the average
characteristic profile of the ‘‘Severe AD’’ group. This allowed the
authors to identify genes with expression levels that correlate with
the characteristic molecular progression from normal cognition to
severe AD. In the current report, we use these quantifiers (which
we will simply term as JSDcontrol and JSDsevere, respectively) as
measures of AD progression, in addition to three common
phenotypic markers (MMSE score, NFT count and Braak staging;
obtained from [3]). We will refer collectively to these measures of
AD progression as ‘progression markers’.
The main objective of this work is to identify a reduced set of pairs
of RNA transcripts that strongly cluster with markers of AD
progression. The analysis of these clusters will also help to identify
individual transcripts that recurrently appear in many pairs, and
may thus guide the selection of candidate molecules for further
research. Towards this end, we apply a large-scale graph-based
clustering approach to datasets derived from the 1,372-probe set
signature identified by Gomez Ravetti et al. [5] to identify
molecular features that correlate with the different ‘progression
markers’. These datasets include the original 1,372-probe set
signature, all pair-wise ratios that can be computed from the
1,372-probe set signature and an expanded dataset containing all
pair-wise differences, summations, ratios and products that can be
computed from the original signature (giving a total of 3,762,024
probe set combinations). We will refer to these probe set pairs as
‘metafeatures’ [9].
To cluster such a large number of metafeatures, we re-
implemented and enhanced the MSTkNN algorithm in [10] by
using the external memory (EM) approaches in [11,12,13].
External memory algorithms are known for their efficiency in
handling large-scale data sets [14,15,16] and the MSTkNN
algorithm is a graph based data clustering algorithm that has
successfully been applied in several applications including the
analysis of stock market time series [17], a gene expression dataset
[18], a prostate cancer trial dataset [19] and has been integrated
with a combinatorial optimization based graph visualization layout
[20]. Our previous work indicates that the MSTkNN algorithm
produces meaningful clusters (see [17,18,20]) and our proposed
modification to this algorithm is still capable of producing
reasonable clustering structure in terms of homogeneity and
separation (Table 1).
After clustering all the metafeatures together with the different
progression markers, we attempt to uncover pairs of probe sets
that jointly cluster with each progression marker. Additionally, we
identify some probe sets in these pairs that not only cluster with
different progression markers but also relate to genes that share
common biological pathways. We annotate these pairs of markers
with the most recent information available. We also look at the
expression of some of these markers in a different transcriptomic
study that involves several regions of the brain in search for
consensus among different studies.
Results
Results for each of the datasets are presented in the following
order: 1. composition of the clusters containing the aforemen-
tioned progression markers, 2. results of functional analyses carried
out using publicly available tools (iHop, Gather, GIM) and 3. a
bibliographic (Pubmed) characterization of certain highlighted
Table 1. Performance comparison of the EM MSTkNN with k-Means, SOM, CLICK and the original MSTkNN algorithms, in terms of
homogeneity and separation.
Data Methods/Algorithm Parameter Havg Savg #Clusters Time
AD Signature data set
(n = 1,372)
k-Means k = 5 0.179 0.121 5 ,0.5 min
k = 120 0.394 0.172 120 ,1 min
SOM 2X5 grid 0.185 0.183 6 ,0.5min
5X5 grid 0.217 0.142 14 ,1 min
CLICK – 0.606 0.245 5 ,1 min
MSTkNN – 0.780 0.369 226 ,0.5 min
EM MSTkNN
(this paper)
– 0.789 0.370 228 ,0.2 min




– Not Available Not Available Not Available Not Available
EM MSTkNN
(this paper)






– 0.879 0.521 121,611 120 min
The implementations of the k-Means, SOM, CLICK algorithms are obtained from the Expander microarray data cluster tool in [124]. The homogeneity and separation are
computed using the definition in [124]. The AD ratio metafeatures data set is generated by taking pair-wise ratios between the features in 1,372-probe AD signatures [5]
and including MMSE score, NFT count, Braak staging, JSDcontrol and JSDsevere as five progression markers. The other data set contains four different types of metafeatures
(ratios, summations, differences and products) and the aforementioned progression markers.
doi:10.1371/journal.pone.0045535.t001
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probe sets. Probe sets are highlighted for several reasons, including
having a strong correlation with one or more progression markers
or appearing in a metafeature with a probe set for another gene
which has a potential role in AD or in other brain disease. The
clustering outcomes are given in File S1, File S2 and File S3.
Where a particular probe set has been highlighted and discussed in
our previous publication on this dataset [5], we refer the reader to
this paper rather than re-iterating discussion points in the present
report.
1,372-probe set signature (File S1)
First, we analysed the 1,372-probe set signature from [5] using
the proposed clustering algorithm and found a total of 228 clusters.
We then identified the clusters that contain the proposed
progression markers (Figure 1 and Table 2).
Cluster containing MMSE score. A total of 11 probe sets
clustered with MMSE score. Among the gene transcripts targeted by
these probe sets, TTN (Titin/Connectin) may have a role in AD
progression through its ability to form amyloid aggregates [21].
The genes ATP5C1, COX4I1, KLHL20, ITGB8 and C10orf76 were
Figure 1. Visualization of the clustering outcome of the 1372-probe set signature. The figure shows only the clusters that contain the
progression markers (hexagonal nodes). We note that the probe set for PTEN, whose product has been recently observed to localize with intracellular
NFTs [36], has values that correlate strongly with the Jensen-Shannon divergence of the severe profile (JSDsevere).
doi:10.1371/journal.pone.0045535.g001
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highlighted by the analysis in Gomez Ravetti et al. [5] and we
refer the reader to this paper for extensive discussion of these genes
in the context of AD. We identified several probe sets that
uniquely cluster with MMSE score and target transcripts for genes
not previously associated with AD. These included PTMS
(parathymosin), a chromatin remodelling protein essential for cell
cycle progression and proliferation of normal and malignant cells,
MKS1 (Meckel syndrome, type 1), mutations in which are
associated with a malformation of central nervous system known
as Meckel syndrome, and SPDEF and a probe set for C19orf50.
Cluster containing NFT count. Two probe sets clustered
with NFT count. These probe sets targeted transcripts for COX6B1
and MMP11, both of which were highlighted in Gomez Ravetti
et al. [5] and will not be discussed in detail here.
Cluster containing braak staging. Three probe sets
clustered with the Braak staging values. These probe sets targeted
transcripts for CASP9 (caspase 9), which was previously highlighted
by the analysis in Gomez Ravetti et al. [5], TNKS (tankyrase) and
CR1 (complement receptor 1), which is genetically associated with
the risk of AD [22,23,24,25,26,27,28,29,30] and entorhinal cortex
volume in young healthy adults [31] (see also [32]).
Clusters containing JSDcontrol and JSDsevere. Two probe
sets clustered with JSDcontrol - these related to the genes ALDOB
(aldolase B, fructose-bisphosphate) and MLLT4 (myeloid/lym-
phoid or mixed-lineage leukemia, translocated to, 4), which is
reportedly involved in the formation and remodelling of synapses
in hippocampus [33]. Three probe sets clustered with JSDsevere.
These related to the genes BTG3 (BTG family, member 3), which
is related to prognosis of neuropathic symptoms in paraneoplastic
neuropathy [34], TREX1 (three prime repair exonuclease 1),
mutations in which can cause a neurovascular disorder involving
progressive cognitive decline due to brain degeneration [35], and
PTEN (phosphatase and tensin homolog). Altered distribution of
PTEN has been reported in degenerating neurons in AD;
specifically, a delocalization from the nucleus to the cytoplasm
and accumulation in intracellular neurofibrillary tangles [36].
Comparing clustering outcomes with statistics-based
outcomes. An alternative method for selecting probe sets highly
correlated with progression markers is to simply perform
regression analysis and identify the probe sets with the highest
correlation coefficient or lowest p-value. In essence this is a
univariate approach, where the selection of a particular probe set
is independent of which other probe sets are selected. In contrast,
the MSTkNN-based clustering method used here is a multivariate
approach which considers the interrelationships of different probe
sets in its selection. As such, we would expect the MSTkNN-based
method to identify features of potential biological relevance that
are missed by univariate approaches.
To investigate the similarities and differences in outcomes of
multivariate and univariate approaches, we compared the probe
sets identified by our clustering method with those having the
highest, most significant correlations by regression analysis (see
Figure S1). For example, we compared the 11 probe sets clustered
with MMSE to the 11 probe sets most significantly correlated with
MMSE by regression analysis. While there were some similarities
in the probe sets identified, there were also important differences.
Notably, some genes of particular relevance to AD were selected
by the clustering method but not by filtering based on statistical
Table 2. Clustering outcomes for the 1372-probe set signature.
Progression Marker Gene Symbol. Probe Set ID Correlation Coefficient KEGG Pathway
MMSE ATP5C1. 213366_x_at 0.764201 ATP synthesis








ITGB8. 205816_at 20.86993 ECM-receptor interaction, Focal adhesion
NM_024849. 220531_at 20.88067
NFT COX6B1. 201441_at 0.564201 Oxidative phosphorylation
MMP11. 203876_s_at 20.290462
Braak CR1. 206244_at 0.363241 Complement and coagulation cascades
CASP9. 210775_x_at 20.240432 Apoptosis, MAPK signaling pathway
TNKS. 216695_s_at 20.287898
JSDcontrol MLLT4. 208512_s_at 0.723242 Adherens junction, Tight junction
ALDOB. 217238_s_at 0.480468 Carbon fixation, Glycolysis
JSDsevere BTG3. 215425_at 0.464201 ATP synthesis
PTEN. 211711_s_at 0.250462 Phosphatidylinositol signaling system, Tight junction
TREX1. 34689_at 0.236458
For each progression marker, probe sets have been ordered according to their Spearman’s rank correlation with the progression marker. Gene symbols in boldface
indicate that they were previously discussed in [5] and gene symbols with underlined boldface represent the cases for which a putative relationship exists in the
published literature between the gene and AD.
doi:10.1371/journal.pone.0045535.t002
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significance. For example, clustering with Braak staging identified
a probe set targeting CR1 which, as mentioned above, is widely
proposed as a genetic risk factor for AD, however this probe set
was not identified by the statistical method.
941,885 Ratio Metafeatures Data Set (File S2)
Next, we conducted a cluster analysis using the proposed
external memory clustering algorithm on the 941,885 metafea-
tures generated by calculating the ratio of each pair of probe sets
from the 1,372-probe set signature [5]. There were a total of
40,139 clusters in the data set, from which we again identified the
clusters that contain the previously mentioned progression
markers.
Cluster containing MMSE score. A total of 32 ratio
metafeatures (containing 35 different probe sets) clustered with
MMSE score (Table 3). The cluster contained metafeatures
involving probe sets for five genes previously studied in the
Table 3. Ratio metafeatures clustered with MMSE score.




PRKCB1.209685_s_at/PTEN.222176_at 20.68675 Phosphatidylinositol signaling system
FOXO1.202724_s_at/ACACA.212186_at 20.78654 Insulin signaling pathway
CASK.211208_s_at/PTEN.222176_at 20.83565 Tight junction
RPL23A.203012_x_at/ATP5C1.213366_x_at 20.83758
CASK.211208_s_at/ATP5C1.213366_x_at 20.86355
ACACA.212186_at/LDHA.200650_s_at 20.87642 Propanoate metabolism
PRKAR2B.203680_at/ACACA.212186_at 20.88001 Insulin signaling pathway
COX6A1.200925_at/ATP5C1.213366_x_at 20.88233 Oxidative phosphorylation
RPL23A.203012_x_at/PPIA.211765_x_at 20.88328
ACTN1.208636_at/VCL.200930_s_at 20.88344 Focal adhesion
ITGB8.205816_at/TTN.208195_at 20.88642 Focal adhesion
ITGB8.205816_at/PTN.209466_x_at 20.88642 Focal adhesion
CPT2.204264_at/ATP5C1.213366_x_at 20.89851
















Metafeatures are ordered by Spearman’s rank correlation with MMSE score. Genes in boldface indicate that they were previously discussed in [5] and genes with
underlined boldface represent the cases for which the gene has been discussed in the context of AD in the published literature.
doi:10.1371/journal.pone.0045535.t003










Metafeatures are ordered by Spearman’s rank correlation with NFT count.
Genes in boldface indicate that they were previously discussed in [5] and genes
with underlined boldface represent the cases for which the gene has been
discussed in the context of AD in the published literature.
doi:10.1371/journal.pone.0045535.t004
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context of AD (TTN [37,38], PPIA [39,40,41], VSNL1
[42,43,44,45,46,47,48], NEFL [49,50,51] and FXYD6 [52]). We
also identified, in different clustered metafeatures, probe sets for 15
other genes (FOXO1, ACACA, CASK, PTEN, PTN, ATP5C1, LDHA,
PRKAR2B, CPT2, DDX1, ITGBL1, TCF7L2, C10orf76, the non-
coding RNA TUG1 and SCFD1) previously highlighted in the
analysis of Gomez Ravetti et al. [5]. Additionally, we found 12
metafeatures in which both of the probe sets comprising the
metafeature relate to genes in a common pathway (Table 3). These
gene pairs were PRKCB1/PTEN (phosphatidylinositol signaling
system), FOXO1/ACACA and PRKAR2B/ACACA (insulin signaling
pathway), ACACA/LDHA (propanoate metabolism), COX6A1/
ATP5C1 (oxidative phosphorylation), TCF7L2/ACTN1 (adherens
junction), CASK/PTEN (tight junction), C10orf76/PPIA (ECM-
receptor interaction), ACTN1/VCL, ITGB8/TTN, ITGB8/PTN
and TTN/PRKCB1 (focal adhesion).
Cluster containing NFT count. Four ratio metafeatures
(containing 8 different probe sets) clustered with NFT count
(Table 4). The probe sets comprising these metafeatures did not
target genes in common pathways but four of them targeted genes
previously highlighted in the analysis of Gomez Ravetti et al. [5]:
ICA1, COX6B1, ATP5C1 and ITGB8.
Cluster containing braak staging. A total of 27 ratio
metafeatures clustered with Braak staging values (Table 5). Three
of these were comprised of probe sets targeting genes that can be
mapped to common KEGG pathways: CR1/SERPINA5 (comple-
ment and coagulation cascades), MDH2/ACO2 (TCA cycle) and
ITGB5/TNXB (ECM-receptor interaction). Of the various probe
sets identified in this cluster, only one targets a gene previously
implicated in AD - CR1 (discussed above). Metafeatures in the
cluster also contained probe sets targeting six other genes
previously highlighted by the analysis of Gomez Ravetti et al.
[5]: PTN, PPT1, RIMS2, ASTN1, ITGB5 and PAX6. Many of the
metafeatures that showed a positive correlation with Braak staging
were dominated by a probe set for LRRC48 (leucine rich repeat
containing 48), a gene which is currently poorly characterized.
Cluster containing JSDcontrol. A total of 93 ratio metafea-
tures (containing a total of 94 different probe sets) clustered with
JSDcontrol (Table 6), see also File S2 for complete list). Three of these
metafeatures comprised probe sets targeting genes in common
KEGG metabolic pathways: LDHA/GOT2 (cysteine metabolism),
Table 5. Ratio metafeatures clustered with Braak staging.




















CR1.206244_at/SERPINA5.209443_at 20.66797 Complement and coagulation
cascades
AL520908.217833_at/LRRC48.208140_s_at 20.68605




ITGB5.201125_s_at/TNXB.216333_x_at 20.86804 ECM-receptor interaction
C15orf39.204494_s_at/LRRC48.208140_s_at 20.89186
Metafeatures are ordered by Spearman’s rank correlation with Braak staging. Genes in boldface indicate that they were previously discussed in [5] and genes with
underlined boldface represent the cases for which the gene has been discussed in the context of AD in the published literature. Most of the positively correlated
metafeatures in this cluster are dominated by LRRC48 (See File S2 for details).
doi:10.1371/journal.pone.0045535.t005
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NDUFA10/ATP5C1 (oxidative phosphorylation) and ATP5C1/
ATP5H (ATP synthesis). The probe sets contained in the clustered
metafeatures targeted six genes that have previously been studied
in the context of AD: PPP2CA [53,54,55,56], SERPINI1
[57,58,59,60,61], OPA1 [62,63,64,65,66], PPIA and CSF1
[67,68,69,70,71,72]. Additionally, we identified probe sets target-
ing 27 other genes previously highlighted by the analysis of Gomez
Ravetti et al. [5]: NUFIP1, ATP6V1D, UQCRQ, DDX1, WASF1,
ATP5C1, COX4I1, SNRK, PPP3CA, LDB2, COX7AP2, LAMTOR2,
LDHA, PBX1, CAPRIN2, SLC25A6, SCFD1, DOPEY1, CSPG5,
TUBG2, NRXN1, CADPS2, CRYM, FZD5, MAPK1, CASP9, PTN
and ICA1. Most of the metafeatures in this cluster that showed a
positive correlation with the divergence from control to severe AD
were dominated by KLK3 (kallikrein 3), also known as prostate
specific antigen, a well-known blood biomarker of prostate cancer
[73]. To determine whether correlations involving KLK3 levels
were influenced by gender, we stratified our dataset by gender. We
performed the clustering again in both gender-specific datasets
and found that KLK3 was completely absent in the same cluster of
the dataset comprising only females. We therefore suggest that
Table 6. Ratio metafeatures clustered with JSDcontrol.



















NDUFA10.217860_at/ATP5C1.205711_x_at 20.86735 Oxidative phosphorylation
ATP5C1.205711_x_at/ATP5H.210149_s_at 20.87348 ATP synthesis
We have selected 20 metafeatures (10 most positively correlated and 10 most negatively correlated) clustered with JSDcontrol and ordered them by Spearman’s rank
correlation with JSDcontrol. Genes in boldface indicate that they were previously discussed in [5] and genes with underlined boldface represent the cases for which the
gene has been discussed in the context of AD in the published literature. Most of the positively correlated metafeatures in this cluster are dominated by KLK3 (kallikrein
3) (See File S2 for details).
doi:10.1371/journal.pone.0045535.t006
Table 7. Ratio metafeatures clustered with JSDsevere.
Metafeature (Gene Symbol. Probe Set ID) Correlation Coefficient Common KEGG Pathways
MLLT4.208512_s_at/PTEN.211711_s_at 0.842239 Tight junction
CYP3A4.205998_x_at/PTEN.211711_s_at 0.777368
MLLT4.208512_s_at/CCDC6.204716_at 0.753547
PRKCB1.209685_s_at/ATP2B2.204685_s_at 20.2207 Calcium signaling pathway
CPNE3.202118_s_at/AL520908.217833_at 20.46933
TGFB2.209909_s_at/PPP2CA.208652_at 20.67022 TGF-beta signaling pathway
FCAR.211307_s_at/AF043586.216394_x_at 20.78256
CYP3A4.205998_x_a/CPT2.204264_at 20.87018 Fatty acid metabolism
N25732.204131_s_at/AF043586.216394_x_at 20.9031
Metafeatures are ordered by Spearman’s rank correlation with JSDsevere. Genes in boldface indicate that they were previously discussed in [5] and genes with underlined
boldface represent the cases for which the gene has been discussed in the context of AD in the published literature.
doi:10.1371/journal.pone.0045535.t007
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Table 8. Ratio-sum-difference-product metafeatures clustered with MMSE score.
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further study of KLK3 in relation to AD should be done in male
patients only.
Cluster containing JSDsevere. Nine ratio metafeatures clus-
tered with JSDsevere (Table 7). For four of these metafeatures, both
probe sets comprising the metafeature targeted genes that can be
mapped to a common KEGG pathway. These metafeatures were
MLLT4/PTEN (tight junction), PRKCB1/ATP2B2 (calcium sig-
naling pathway), TGFB2/PPP2CA (TGF-b signaling pathway),
CYP3A4/CPT2 (fatty acid metabolism). Metafeatures in this cluster
contained probe sets for three genes previously investigated in the
context of AD (CYP3A4 [74,75,76], ATP2B2 [77,78] and PPP2CA)
and four other genes previously highlighted by the analysis of
Gomez Ravetti et al. [5] (PTEN, PRKCB1, FCAR and CPT2).
Estimation of False Discovery Rate
Investigating a very large data space, such as that occupied by
the many possible metafeatures, will inevitably lead to a number of
false positive findings. In order to estimate the false discovery rate
at different correlation coefficient thresholds, and therefore
demonstrate the validity of our approach in identifying more than
just random events, we performed a simple a Monte-Carlo
permutation test by randomly permuting the MMSE scores of the
17 samples and computing the correlation of each metafeatures
with the permuted MMSE labels. The results after 1,000
permutations reveal that, at all thresholds tested, there is clearly
a higher number of strongly correlated metafeatures among our
ratio metafeatures dataset than would be expected by chance
alone (see Figure S2, Figure S3, Figure S4 and Figure S5).
3,763,403 Ratio-sum-difference-product Metafeatures Data
Set (File S3)
We next applied our clustering algorithm to a data set of
3,763,403 metafeatures. This dataset was produced by calculating
all pair-wise differences, summations, ratios and products of the 1,372-
probes identified in Gomez Ravetti et al. [5].
The algorithm created a total of 121,611 clusters for the data
set. We identified one larger cluster containing all of the
progression markers. Due to the large number of metafeatures
in the cluster, we focused only on the metafeatures with the
strongest positive and negative correlations with each of the
progression markers. We refer to File S3 for the details of this
cluster.
Metafeatures correlating with MMSE Score. From the list
of 50 metafeatures most strongly correlated (25 positively and 25
negatively) with MMSE score, we identified five that involve probe
sets that target genes in common KEGG pathways (Table 8). This
list of metafeatures also involved probe sets targeting genes
previously investigated in the context of AD (PPIA, TTN, FXYD6,
VSNL1, SERPINI1(see above), PLCB1 [79,80,81], IL15 [82,83,84],
NRG1 [85,86,87], SERTAD2 [88]) and genes highlighted by the
analysis in Ravetti et al. [5] (ICA1, ITGB8, GABBR2, CSPG5,
ATP2B2, C10orf76, PRKAR2B, ACACA, MYT1L, KLHL20, PTEN,
LDHA, AFF1, TUG1, RBM19, CPT2, ZBTB20, ITGBL1). We refer
the reader to the paper of Gomez Ravetti et al. [5] for discussion
of these genes in the context of AD.
Metafeatures correlating with NFT count. From the list of
50 metafeatures most strongly correlated with NFT count, four
comprised probe sets targeting genes in common pathways
(Table 9). There were also probe sets targeting genes previously
investigated in the context of AD (PPIA, TTN, MCL1 [89], UPF1
[90], RGS4 [91,92,93,94]) and some other genes highlighted by the
analysis in Gomez Ravetti et al. [5] (GNA14, C10orf76, MMP11,
TCF7L2, COX6B1, PRKCI, ICA1).
Metafeatures correlating with braak staging. From the
list of 50 metafeatures most strongly correlated with Braak staging,
five comprised probe sets targeting genes in common pathways
(See Table 10). Only one gene previously proposed to be involved
in AD, CR1 (see above), was targeted by a probe set within the 50
metafeatures. Probe sets targeting some important genes high-
lighted by the analysis of Gomez Ravetti et al. [5] (COX4I1,
CASP9, ITGB1, RHOQ, DLGAP2, GSTA3, BCL2, COX6A1 and
ATP5C1) were also found in this set of metafeatures.
Metafeatures correlating with JSDcontrol. From the list of
50 metafeatures most strongly correlated with JSDcontrol, four
comprised probe sets targeting genes in common pathways
(Table 11). We also identified metafeatures comprising probe sets
targeting various genes highlighted in the analysis in Gomez
Ravetti et al. [5] (RBM19, KCNK5, AGTR1, TUBD1, GABRQ,
MMP11, ZNF669, TBXA2R, NUFIP1, LDHA, ICA1).
Metafeatures correlating with JSDsevere. From the list of
50 metafeatures most strongly correlated with JSDsevere, six
comprised probe sets targeting genes in common pathways
(Table 12). We also identified metafeatures comprising probe sets
targeting genes previously studied in the context of AD (VSNL1,
PPP2CA, CYP3A4 (see above)) and genes highlighted by the
analysis in Gomez Ravetti et al. [5] (PTEN, MAPK1, COX6A1,
GABRQ, FCAR, FZD5, PIP5K1C, SHANK2, CPT2).
Comparison of Metafeature Correlations and Single
Probe Set Correlations
The observation of particular probe sets recurring in multiple
clustered metafeatures raises the question of whether the clustering
of certain metafeatures is driven by a strong correlation between a
progression marker and only one of the two individual probe sets
comprising a metafeature. To investigate this possibility, we
separately assessed the correlation of the two probe sets comprising
a metafeature with the progression marker in question and
compared this to the correlation between the metafeature and the
progression marker.
Deeper analysis of the ‘‘ratio metafeatures’’ that clustered with
MMSE scores reveals a number of metafeatures where individual
Table 8. Cont.
Metafeature (Gene Symbol. Probe Set ID) Correlation Coefficient Common KEGG Pathways
AL359052.214927_at/ATP5C1.205711_x_at 20.9188
KLHL20.204177_s_at+SDC1.201287_s_at 20.9188
We have selected 50 metafeatures (25 most positively correlated and 25 most negatively correlated) and ordered them by Spearman’s rank correlation with MMSE
score. Genes in boldface indicate that they were previously discussed in [5] and genes with underlined boldface represent the cases for which the gene has been
discussed in the context of AD in the published literature (see File S3 for details).
doi:10.1371/journal.pone.0045535.t008
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Table 9. Ratio-sum-difference-product metafeatures clustered with NFT count.














































COX6B1.201441_at/ATP5C1.213366_x_at 20.87976 Oxidative phosphorylation
COX6B1.201441_at+RGS4.204339_s_at 20.88473
ALDOB.217238_s_at-PRL.205445_at 20.89422
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probe sets (one or both) are not significantly correlated (p.0.05)
with MMSE (see Table S1). This suggests that the high correlation
of certain metafeatures does not simply reflect an additive effect of
its two component probe sets (see Figure S6) but instead is driven
by the dynamics of the interrelationship (possibly a biological
interaction) between the two transcripts that are targeted.
For specific examples we refer to Figure 2 where we
demonstrate an example scenario with the three probe sets
targeting TTN, CASK and TUG1 and the metafeatures TTN/
PKRCB1, CASK/PTEN and TUG1/SCFD1. In this example, the
metafeatures show a better correlation with MMSE score than the
relevant individual probe sets (Figure 2). In general, we found that
if both the probe sets in a metafeature target genes in a common
pathway, then the metafeature shows better correlation with the
progression marker than either of the two individual probe sets.
For example, TTN and PKRCB1 both appear in the ‘focal
adhesion’ KEGG pathway and CASK and PTEN in both appear in
‘tight junction’ pathway.
There were various instances in which the individual compo-
nents of highly correlated metafeatures did not map to a common
KEGG pathway. For example, a metafeature containing probe
sets for TUG1 and SCFD1 shows a better correlation with MMSE
score than either probe set individually. However it is not
surprising that these transcripts do not map to a common
pathway, as long ncRNAs such as TUG1 are relative newcomers
to functional annotation.
It should be noted, however, that a high proportion of the
metafeatures (.90%) showed comparatively better correlations
with the progression markers than the individual probe sets
comprising these metafeatures. While this is not a universal
phenomenon (see Figure S6 and Table S1 for examples, where
two probe sets that are highly correlated with a progression marker
combine to create a poorly correlated metafeature), in view of the
larger data space occupied by the metafeatures, it is logical that the
metafeature analysis may yield an increased proportion of
spurious, false positive results. This is supported by the observed
difference in the estimated false discovery rate of two datasets of
different sizes (see Table S2 and Table S3). In an attempt to avoid
such results, we subsequently focus on ‘robust’ findings – probe
sets that recurrently cluster with different markers of AD
progression.
Robust Markers of AD Progression
We next attempted to identify probe sets that appeared
recurrently in the metafeatures and also clustered with different
markers of AD progression. We depict this group of probe sets in a
5-way Venn diagram (Figure 3 and Figure 4). In these figures, a
null (Q) symbol means that even if an overlap is shown in the
figure, there is no common transcript. From the 941,885 ratio
metafeatures data set, we identified 11 probe sets that, as part of
metafeatures, clustered with more than one progression marker.
The genes targeted by these probe sets were PPIA, ATP5C1,
LDHA, DDX1, SCFD1, ITGB8, PTEN, PRKCB1, CPT2, ICA1 and
PTN. From the 3,763,403 ratios-sum-difference-product metafeatures
data set, there were 13 probe sets that, as part of metafeatures,
clustered with more than one progression marker. The genes
targeted by these probe sets were PPIA, TTN, C10orf76, ICA1,
MMP11, RBM19, LDHA, COX6A1, GABRQ, CPT2, PTEN, VSNL1
and ATP5C1. Notably, six genes were identified as clustering with
more than one progression marker in both metafeature datasets:
PPIA, ATP5C1, LDHA, PTEN, CPT2 and ICA1. We refer the
readers to the Table S4 and Table S5, for further details of
correlation of these markers to the phenotypes.
Validation of Robust Markers in an Alternative Dataset
In order to gain insights into whether the robust markers
highlighted above are restricted to the hippocampus or show
changes in other AD-affected brain regions, we utilized an
independent dataset contributed by Liang and colleagues
[95,96]. This dataset contains microarray data on gene expression
in neurons isolated from four different regions of control and AD
brain: entorhinal cortex (EC), hippocampus (HIP), middle
temporal gyrus (MTG) and posterior cingulate cortex (PC).
Molecular signatures of each different region were generated as
described in Materials and Methods. Several of the ‘robust’ probe
set markers highlighted by our current analysis of hippocampal
tissue were also selected in the molecular signatures of two or more
regional neuronal populations. For example, PPIA and ATP5C1
showed expression changes in neurons isolated from the MTG and
PC of AD brain relative to control brain, PTEN showed expression
changes in the HIP and PC and ICA1 showed expression changes
in the HIP, MTG and PC (Figure 5). In addition, Visinin-like 1
(VSNL1), highlighted in the analysis in Gomez Ravetti et al. [5] as
one of the best markers of AD progression and recently proposed
as one of the four best CSF biomarkers of early AD [97], showed
expression changes in neurons isolated from EC, MTG and PC
(Figure 5) and has been shown in an additional dataset to have
altered expression in various brain regions in AD [98].
Discussion
The present study has extended on our previous analysis in [5]
by (i) considering variables that represent the interrelationship
between two RNA transcripts (i.e. metafeatures) and (ii) applying a
novel and powerful graph-based clustering approach to identify a
reduced set of transcripts or transcript pairs that correlate strongly
with markers of AD progression. This clustering approach is
facilitated by the implementation of an external memory
algorithm on a graphical processing unit, which allows clustering
of massive datasets (in this case involving four million elements)
that is not feasible using standard computational methods.
Table 9. Cont.
Metafeature (Gene Symbol. Probe Set ID) Correlation Coefficient Common KEGG Pathways
ICA1.207949_s_at+NPAL3.210267_at 20.89588
COX6B1.201441_at+SORBS2.204288_s_at 20.89721
We have selected 50 metafeatures (25 most positively correlated and 25 most negatively correlated) and ordered them by Spearman’s rank correlation with NFT count.
Genes in boldface indicate that they were previously discussed in [5] and genes with underlined boldface represent the cases for which the gene has been discussed in
the context of AD in the published literature (see File S3 for details).
doi:10.1371/journal.pone.0045535.t009
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Table 10. Ratio-sum-difference-product metafeatures clustered with Braak staging.
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In addition to identifying transcripts and metafeatures that
correlate with established phenotypic markers of AD severity (i.e.
MMSE score, NFT count, Braak staging), we utilized two addition
quantifiers of AD progression, based on Jensen-Shannon diver-
gence, to identify transcripts and metafeatures that correlate with a
putative molecular trend from control to severe AD. It remains to
be seen whether these quantifiers provide a more accurate
assessment of AD severity, however there are several promising
attributes that suggest this is the case. Firstly, the Jensen-Shannon
divergence values are based on a set of 1,372 different transcript
markers, in contrast to the univariate markers of neuropathology
or cognitive function. Secondly, some of the changes observed at
the transcriptional level may underlie AD pathogenesis, whereas
phenotypic consequences are more likely to simply reflect the
molecular perturbations that drive disease pathogenesis. The
results presented here indicate that a number of probe sets that are
highly correlated with Jensen-Shannon divergence are also highly
correlated with more traditional phenotypic markers of AD
progression. Our previous studies using these quantifiers in the
context of AD [5] and cancer [99] have also yielded high
consensus with established markers of disease progression.
Together, these findings give us confidence that metrics based
on multivariate transcriptional changes can act as reliable markers
of disease stage.
The analyses reported here demonstrate that, although there
exists a relatively large molecular signature associated with AD
progression, a relatively small number of transcripts appear
recurrently in metafeatures clustered with the progression markers.
This allowed a focussed investigation of a reduced set of
biomarkers that have been previously studied in the context of
cognitive decline and AD. Furthermore, our approach also put
emphasis on a few novel markers that have not been discussed
previously in relation to AD progression and warrant further
investigation.
While it is outside the scope of this paper to discuss in detail all
of the genes identified in the analyses, focussed discussion of some
of the most robust findings is warranted. As mentioned at the end
of the Results, as set of six genes (PPIA, ATP5C1, LDHA, PTEN,
ICA1, CPT2) recurrently appeared in metafeatures and clustered
with more than one progression marker in both metafeature
datasets. Furthermore, changes in expression of several of these
genes were validated in an alternative microarray dataset of
neurons from different AD-affected brain regions, lending further
support to the proposal that altered expression of these genes may
be involved in AD pathogenesis.
Peptidylprolyl isomerase A (PPIA), also known as cyclophilin
A, is believed to accelerate protein folding. Evidence from neural
cell lines suggests PPIA can protect against Ab-induced oxidative
stress, possibly by acting as a ROS scavenger [100]. Proteomics
studies have revealed decreased expression of PPIA in brains of
patients with non-Alzheimer’s disease tauopathies [41], suggest-
ing alterations in PPIA may be associated with the general
process of neurodegeneration rather than AD specifically.
Curiously, PPIA has been proposed as a suitable reference gene
for PCR studies of AD brain due to its stable expression
[101,102]. The results of our analysis strongly argue against this
and instead indicate that PPIA expression, particularly when
considered as part of a metafeature, is strongly correlated with
AD progression.
ATP synthase subunit gamma (ATP5C1) encodes a subunit of
mitochondrial ATP synthase, important for catalyzing ATP
synthesis in oxidative phosphorylation. While this gene has not
previously been implicated in AD, its transcriptional correlation
with AD progression may reflect disturbances in energy produc-
tion as a result of cellular loss.
Lactate dehydrogenase A (LDHA), another metabolic gene, is
responsible for catalysing the conversion of lactate to pyruvate, the
final step in anaerobic glycolysis. A recent study has demonstrated
that increased LDHA activity is a feature of nerve cell lines that
are resistant to Ab-induced cell death and that the phenomenon of
aerobic glycolysis might contribute to the mechanisms by which
certain neurons in the AD brain survive apoptosis [103].
Phosphatase and tensin homolog (PTEN) has generally been
studied in the context of cancer, as it is a tumor suppressor with
phosphatase activity that negatively regulates the AKT/PKB
signalling pathway. However PTEN has also been shown to be
necessary for proper migration of neurons and glia [104]. There
is decreased expression and altered distribution of PTEN in AD
brain [105,106], where it localizes with neuritic pathology such
as neurofibrillary tangles in damaged neurons [36]. PTEN
affects phosphorylation and aggregation of tau [106,107] and
appears to be regulated by presenilin, as presenilin deficient
neurons show a substantial reduction in PTEN [108]. Further-
more, mutations in the PTEN induced putative kinase 1
(PINK1) gene have been linked to early-onset familial
Parkinson’s disease [109,110], while ablation of PTEN in
dopaminergic neurons is neuroprotective in mouse models of
Parkinson’s disease [111].
Islet cell autoantigen 1 (ICA1) is believed to be an autoantigen
in insulin-dependent diabetes mellitus. ICA1 is the major binding
partner of PICK1 and together these proteins regulate trafficking
of AMPA glutamate receptors to the synapse [112]. It has also
been proposed that ICA1 participates in the process of neuroen-
docrine secretion through association with certain secretory
vesicles [113].
Carnitine palmitoyltransferase 2 (CPT2) is involved in the
oxidation of long-chain fatty acids in the mitochondria. This gene
has not previously been associated with AD.
In addition, we highlight some relevant genes that correlated
with more than one progression marker in one of the metafeature
Table 10. Cont.
Metafeature (Gene Symbol. Probe Set ID) Correlation Coefficient Common KEGG Pathways
CASP9.210775_x_at+DENND4A.214787_at 20.89462
CASP9.210775_x_at-RGS3.220300_at 20.90202
We have selected 50 metafeatures (25 most positively correlated and 25 most negatively correlated) and ordered them by Spearman’s rank correlation with Braak
staging. Genes in boldface indicate that they were previously discussed in [5] and genes with underlined boldface represent the cases for which the gene has been
discussed in the context of AD in the published literature (see File S3 for details).
doi:10.1371/journal.pone.0045535.t010
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Table 11. Ratio-sum-difference-product metafeatures clustered with JSDcontrol.


























MTHFD1.202309_at/MDH2.213333_at 20.67409 Glyoxylate and dicarboxylate metabolism
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datasets. Protein kinase C beta, encoded by PRKCB1, is involved
in a wide range of signalling pathways. Increased expression of
protein kinase C beta has been observed in membrane fractions of
aged Tg2576 mice, a model of AD [114]. Furthermore, one of the
best biomarkers in [5], visinin-like 1 (VSNL1), is only expressed in
neurons and shows decreasing expression as AD progresses. Levels
of VSNL1 in the CSF have recently been proposed as an effective
biomarker of early AD [97].
It is interesting to remark that the individual markers identified
in this study are bringing new insights to the pathological
mechanisms involved in AD but that an integrative approach is
required to understand them. For example, increased VSNL1 in
the CSF observed in [97] may be a consequence of increasing
neuronal death rather than an marker of early AD. On the other
hand, as LDHA expression is currently being considered as a
possible marker of aerobic glycolysis in Ab-resistant neurons [103],
the correlation between LDHA expression and AD progression
makes sense if we think that Ab-resistant neurons will be
proportionally more abundant in samples with greater disease
severity.
One limitation of the present study is that the low number of
samples (17) available for these analyses may have resulted in a
large number of highly correlated probe sets or metafeatures that
are false positives (see Figure S2, Figure S3, Figure S4, Figure S5,
for a validation of our correlations). The selection of just a few
features out of this large data space has been a critical task that we
attempted to solve by focusing on those which appear most
recurrently. Unfortunately, there are strong possibilities that even
with a set of random data and a very large search space, a set of
false positive markers may recurrently appear. However, since a
relatively higher number of published AD studies can already be
found that implicate these markers, we feel comfortable in making
the claim that they warrant further investigation in future AD
research.
The results presented here support the hypothesis that
systematically considering relationships between two or more
features (‘‘metafeatures’’) can improve biomarker discovery,
particularly when explored within a multivariate framework.
While univariate approaches may still provide important and
complementary insights to those obtained using multivariate
methods, we believe that utilizing both approaches in conjunction
is likely to produce the most robust and relevant findings.
Computational advances such as the external memory implemen-
tation of our clustering algorithm will hopefully make investiga-
tions of this type more commonplace, and we are currently
working towards more sophisticated parallel applications that




This analysis draws on the data set contributed by Blalock et al.
[3] which can be accessed from the NCBI Gene Expression
Omnibus under the accession number GSE1297. The Blalock
study used Affymetrix HG-U133A microarrays to generate data
on 22,286 probe sets. From this dataset, we focused our analysis on
the 1,372-probe set signature identified by Gomez Ravetti et al.
[5].
The Blalock study assessed gene expression in hippocampal
tissue samples from 31 participants. Participants were categorized
into one of four clinical groups using the MMSE criterion:
‘‘Control’’ (MMSE .25, n = 9),‘‘Incipient AD’’ (MMSE 20–26,
n = 7), ‘‘Moderate AD’’ (MMSE 14–19, n = 8) or ‘‘Severe AD’’
(MMSE ,14, n = 7). Borderline cases (e.g. MMSE = 26) were
resolved using NFT count and Braak staging data [115].
In the present study, instead of using all 31 samples, we
excluded 14 samples that had gene expression profiles similar to
the representative profile of the ‘‘Control’’ group (n = 7) or similar
to the representative profile of the ‘‘Severe AD’’ group (n = 7). The
17 remaining samples correspond to the central 17 columns of the
supplementary material ‘File S2 (sheet:1372-probe)’ of [5] and the
data set containing the signature of Gomez Ravetti et al. [5] for
these 17 samples is termed 1,372-probe set signature throughout the
paper. Our rationale for excluding these 14 samples is two-fold.
Firstly, little information about disease progression is likely to be
gained by considering participants at either extreme of a disease
spectrum. Control participants will not have developed any
molecular characteristics of early AD and participants with severe
AD may have already progressed to the disease endpoint.
Secondly, as the ‘‘Control’’ and ‘‘Severe AD’’ groups were used
to generate the 1,372-probe set signature, inclusion of these
samples would likely influence correlations in a biased way. By
excluding these samples, we can assess correlation with AD
progression in a truly independent ‘test’ set of samples.
The advantages of using pair-wise relational features (i.e.
metafeatures) have recently been demonstrated by Rocha de
Paula et al. [116] in the context of plasma protein biomarkers for
the early detection of AD. We therefore expanded the 1,372-probe
set signature by applying different operators between each possible
pair of probe sets. This led to the creation of two ‘‘artificial’’ data
sets:
N The first data set includes all the pair-wise ratios of the gene
expression values in 1,372-probe set data. It contains a total of
941,885 probe sets, metafeatures and progression markers. We
refer to this data set as the 941,885 ratio metafeatures data set.
N The second data set includes all the pair-wise differences,
summations, ratios and products of the gene expression values in
Table 11. Cont.
Metafeature (Gene Symbol. Probe Set ID) Correlation Coefficient Common KEGG Pathways
KCNJ5.208397_x_at-CASP4.213596_at 20.86111
NDUFA10.217860_at/ATP5C1.205711_x_at 20.86735 Oxidative phosphorylation
We have selected 50 metafeatures (25 most positively correlated and 25 most negatively correlated) and ordered them by Spearman’s rank correlation with JSDcontrol.
Genes in boldface indicate that they were previously discussed in [5] and genes with underlined boldface represent the cases for which the gene has been discussed in
the context of AD in the published literature (see File S3 for details).
doi:10.1371/journal.pone.0045535.t011
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Table 12. Ratio-sum-difference-product metafeatures clustered with JSDsevere.












MLLT4.208512_s_at/PTEN.211711_s_at 0.842239 Tight junction
PPP2CA.208652_at/PTEN.211711_s_at 0.842212 Tight junction
P2RY10.214615_at-AL050026.216626_at 0.842191

































CYP3A4.205998_x_a/CPT2.204264_at 20.87018 Fatty acid metabolism
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1,372-probe set data. It contains a total of 3,763,403 probe
sets, metafeatures and progression markers. We refer to this
data set as the 3,763,403 ratio-sum-difference-product metafeatures
data set.
In each of these two data sets, we have included the original
1,372-probes gene expression signature and five measures of AD
progression: MMSE score, NFT count and Braak staging from
Blalock et al. [3] and the Jensen-Shannon divergences, JSDcontrol and
JSDsevere, from Ravetti et al. [5]. We assume here that correlation
between the values associated with these measures and microarray
probe set expression values can highlight important biomarkers of
AD progression.
Data Clustering
We have adapted, enhanced and re-implemented the MSTkNN
graph partitioning algorithm in [10] to cluster the features in the
large data sets. The proposed method utilizes a graph partitioning
approach that optimizes both the local minimum (by using the
kNN graph) and global minimum (by using the MST). Therefore,
the clusters presented are not necessarily a sorted a list of probes
by their correlation to the phenotypes.
The algorithm first constructs an undirected and complete
graph from the data set where each node is a biological feature
and each edge represents a correlation between two features.
Then, the algorithm starts the clustering process by computing two
proximity graphs: a minimum spanning tree (GMST) and a k-
nearest neighbour graph (GkNN); where the value for k is adaptively
selected from the following equation:
k~minftln (n)s,mink=GkNN isconnectedg ð1Þ
Subsequently, the algorithm inspects all edges in GMST. If for a
given edge (x,y) neither x is one of the k nearest neighbors of y, nor y
is one of the k nearest neighbors of x, the edge is eliminated from
GMST. This results in a new graph G’= GMST – {(x,y)}. Since GMST
is a tree, after the first edge is deleted G’ is now a forest, as it is a
graph that composed of two subtrees. The algorithm continues
applying the same procedure to each subtree in G’ thus generated
(with a value of k re-adjusted by eq. (1) above where n is now the
number of nodes in each subtree), until no further partition is
possible. The final partition of the nodes of G’ induced by the
forest is the result of the clustering algorithm.
Figure 6. Demonstration of the modified MSTkNN
algorithm. (a) An MSTp created from a data set with
n = 10 features/probe sets. Each edge is labeled with an
integer value p, where the value of p is determined using a sorted
list of nearest neighbors for each feature (see eq. (2)). The edge
between F9 and F10 is a candidate for elimination, since it has a
value of p. tln (10)s= 2 (b) Two connected components are
identified and we apply the same procedure with the component
that has more than three elements. (c) The final outcome of the
clustering.
The original algorithm requires(n|(n{1)=2) distance values
(between all pairs of the n elements) as the input. For a large data
set, this may be too large to fit in the computer’s in-memory and,
for even larger values of n, it may not even fit in external memory.
Even if we can store the distance matrix in the external memory,
the computational speed will slow down dramatically because of
the increased number of I/O operations. Therefore, we modified
this step and instead of creating the complete graph from the
distance matrix, we create a q-nearest neighbor graph (GqNN),
where q = tln (n)s+1. This procedure reduces the input graph size,
but still creates a reasonable clustering structure of the data set.
The value of the q is determined from the inclusion relationship [117]
of the GMST and the family of the nested sequence of graphs (GkNN,
where k . ln(n)).
Next, we compute the MST of the GqNN graph. We term it as,
GMSTp. We annotate each edge in GMSTp according to the following
procedure: for each edge (a,b) in E(GMSTp) we assign an integer
value p such that if f(a,b) is the index of b in the sorted list of nearest
neighbors of a in GqNN, the value of p is given by,
p~min f a,bð Þ,f b,að Þf g ð2Þ
We define the maximum value of p in the MSTp (or any of its
components) as pmax and then, we partition the GMSTp with the
following criteria:
C1. If p. tln (n)s; remove the edge,
C2. If pmax , tln (n)s; remove the edges with weight pmax –1,
and;
C3. If pmax = 1 or pmax = tln (n)s; do not remove any edge and the
result is a ‘‘cluster’’.
The final output of our algorithm is a set of partitions or
clusters of the input data (See Figure 6). The algorithm does not
require any pre-determined value for q but it is possible to
change the threshold from tln (n)s to any other user-defined
parameter. The complete algorithm can be found in [13]. To
accelerate the data preprocessing we employed General Purpose
Graphics Processing Unit (GPGPU) computing and implement-
ed a fast and scalable approach to compute the distance metrics
and the q-nearest neighbor graph (GqNN). An illustrated example
of our GPU-based nearest neighbor search algorithm is given in
File S4.
To create the MST from large data set we adapted the EM
MST algorithm in [11] and modified it to annotate the edges
according eq. (4). The I/O complexity of this algorithm is
O(sort(m)Nlog(n/M)), where n is the number of nodes of the original
Table 12. Cont.
Metafeature (Gene Symbol. Probe Set ID) Correlation Coefficient Common KEGG Pathways
N25732.204131_s_at/AF043586.216394_x_at 20.9031
C3orf63.209285_s_at*DDN.214788_x_at 20.90361
We have selected 50 metafeatures (25 most positively correlated and 25 most negatively correlated) and ordered them by Spearman’s rank correlation with JSDsevere.
Genes in boldface indicate that they were previously discussed in [5] and genes with underlined boldface represent the cases for which the gene has been discussed in
the context of AD in the published literature (see File S3 for details).
doi:10.1371/journal.pone.0045535.t012
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Figure 2. Comparison of single probe set correlations and metafeature correlations. Figure shows plots of the correlation with MMSE
score of three probe sets targeting TTN, CASK and TUG1 and three metafeatures involving these probe sets (TTN/PKRCB1, CASK/PTEN and TUG1/
SCFD1). In this example, the correlations between MMSE score and the metafeatures are much better than the correlation between MMSE score and
the individual probe sets.
doi:10.1371/journal.pone.0045535.g002
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graph, m is number of edges and M number of nodes that fit into
computer’s internal memory, respectively, and the sort(m) is the
time required for sorting the m edges. After partitioning the MST,
we identify the connected components using the EM connected
component algorithm in [11,12,118]. The I/O complexity of this
algorithm is O(mNlog(log(n)). Unlike other clustering tools, we store
the connected components/clusters in external memory and only
keep the list of the components in computer’s in-memory. This
eliminates the excessive use of the in-memory even when there are
a large number of components or clusters. Additionally, we tuned
the implementations of the adapted algorithms [11,12,118] for
better performance with denser graphs. Since our algorithm has
been implemented in external memory approach, we term our
algorithm as EM MSTkNN algorithm. Please note here that our
proposed method can be implemented either in-memory or
external memory paradigm. To make this method further scalable,
we have taken the advantages of external memory algorithms and
environments.
The computational tests were performed on a Xenon Nitro
T5 Supermicro server (16 CPU cores, 32 GB RAM, 4x
NVIDIA Tesla C2050 ‘‘Fermi’’ GPU cards (1792 GPU Cores
and 12 Gb RAM total) and 800GB Hard-disk) and the
programs were written in C/C++ with the support of CUDA
[119], STL, STXXL [120] and BOOST [121] library and
compiled using the g++ and nvcc compiler on a Linux
operating system with kernel version 2.6.9.
Figure 3. Venn diagram of the different transcripts clustered with progression markers in the 941,885 metafeatures data set. This
figure highlights the ‘robust correlating’ transcripts that are shared by different progression marker clusters. A null (Q) symbol here means that even if
an overlap is shown in the figure, there is no common transcript. We refer the readers to Supporting Information Table S4., for further details of
correlation of these markers to the phenotypes.
doi:10.1371/journal.pone.0045535.g003
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Monte-Carlo Random Permutation Test
Assessing correlations involving a large number of metafea-
tures and a small number of samples has the potential to lead
to spurious, false positive results. To estimate the false discovery
rate when assessing correlations involving metafeatures, we
performed a simple a Monte-Carlo permutation test, a useful
resampling test when there are many possible orderings of the
samples. In this test, we randomly permuted (rearranged) the values
of the progression marker in question and computed the correlation
of each metafeature against it. A total of 1,000 iterations of the test
were performed and the average number of metafeatures passing
various correlation coefficient thresholds determined.
Functional Annotation
After performing the clustering on the expanded data sets, we
identified the specific clusters that contained the progression markers
Figure 4. Venn diagram of the different transcripts clustered with progression markers in the 3,763,403 metafeatures data set. This
figure highlights the ‘robust correlating’ transcripts that are shared by different progression marker clusters. A null (Q) symbol here means that even if
an overlap is shown in the figure, there is no common transcript. We refer the readers to Supporting Information Table S5., for further details of
correlation of these markers to the phenotypes.
doi:10.1371/journal.pone.0045535.g004
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(MMSE score, NFT count, Braak staging, JSDcontrol and JSDsevere) and
analysed the correlation (using Spearman’s rank computation) of the
clustering probe sets or metafeatures with these progression markers.
If the size of the cluster was very big, we noted the top most positively
and negatively correlated probe sets or metafeatures.
GATHER [122], a popular online tool for interpreting genomic
signatures, was used to assess possible biological relationships
between the two transcripts targeted by the probe sets comprising
a metafeature. We checked each of the clustering metafeatures to
determine if the relevant transcripts share any common biological
pathway (KEGG pathways). Our objective here is to detect the
pair of transcripts that not only appear in the same pathway but
also jointly activate the progression of AD.
Validation Using an Alternative Dataset
For validation of changes in select genes, we analyzed the dataset
contributed by Liang and colleagues [95,96], which can be accessed
from NCBI Gene Expression Omnibus under the accession number
GSE5281. This microarray dataset was generated using Affymetrix
Human Genome U133 Plus 2.0 Arrays and assessed gene
expression in healthy neurons isolated by laser capture microdis-
Figure 5. Validation of robust markers of AD progression in an alternative dataset. Transcript levels for selected genes of interest were
investigated in the microarray dataset of Liang and colleagues [95,96], which assessed gene expression in healthy neurons isolated from four different
regions of control and AD brain: entorhinal cortex (EC), hippocampus (HIP), middle temporal gyrus (MTG) and posterior cingulate cortex (PC). Data
presented in this figure were normalized using Robust Multichip Average (RMA). In the box and whisker plots, the bottom and top of the box
represent the lower and upper quartiles, respectively, and the band within the boxes represents the median, while the ends of the whiskers represent
the minimum and maximum values.
doi:10.1371/journal.pone.0045535.g005
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section from different regions of post-mortem control and AD brain.
We refer the reader to [95,96] for full experimental details.
In the analyses presented here, we investigated gene expression in
the entorhinal cortex (13 controls, 10 AD), hippocampus (13 controls,
10 AD), middle temporal gyrus (12 controls, 16 AD) and posterior
cingulate cortex (13 controls, 9 AD). Microarray data were
normalised with RMA in the Affymetrix Expression Console (v1.1).
For each region, genetic signatures that discriminate control and AD
samples were generated as described in [5]. Briefly, data were first
preprocessed by discretization of the expression values using an
implementation of Fayyad and Irani’s algorithm [6], an entropy-
based heuristic. This was followed by a filtering step to discard probe
sets that do not provide sufficient information to discriminate between
the control and AD classes, based on the Minimum Description
Length principle (reviewed in [123]). The matrix of discrete values
returned after entropy filtering was then used to create an instance of
the (a,b)-k-Feature Set problem (for details see [123]). The optimal
solution to this problem was used as the genetic signature.
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